Table 6. Combined effects of SNPs (rs4027405, rs1890908) and serum AFP level.
| SNP | MST (months) | Crude HR (95% CI) | P | Adjusted HR* (95% CI) | P* |
|---|---|---|---|---|---|
| rs4027405 | |||||
| AFP ≤ 400+AA | 68 | Ref. | 0.005 | Ref. | 0.012 |
| AFP ≤ 400+AG/GG | 52 | 1.27 (0.87–1.87) | 0.220 | 1.09 (0.69–1.72) | 0.703 |
| AFP > 400+AA | 39 | 1.63 (1.05–2.52) | 0.029 | 1.63 (1.00–2.65) | 0.048 |
| AFP > 400+AG/GG | 28 | 2.25 (1.40–3.61) | 0.001 | 2.25 (1.31–3.87) | 0.003 |
| rs1890908 | |||||
| AFP ≤ 400+GG | 68 | Ref. | 0.006 | Ref. | 0.018 |
| AFP ≤ 400+AG/AA | 52 | 1.24 (0.86–1.79) | 0.254 | 1.09 (0.71–1.69) | 0.683 |
| AFP > 400+GG | 39 | 1.62 (1.04–2.52) | 0.031 | 1.63 (1.00–2.66) | 0.050 |
| AFP > 400+AG/AA | 28 | 2.23 (1.40–3.78) | 0.001 | 2.21 (1.26–3.88) | 0.006 |
HR = hazard ratio, 95% CI = 95% confidence interval, MST = median survival time, Ref. = reference.
*Adjustment for age, gender, BMI, race, smoking status, drinking status, child-pugh class, cirrhosis, BCLC stage, pathological grade, TACE status post hepatectomy, antiviral therapy after hepatectomy, radical resection, intrahepatic metastasis, vascular invasion and PVTT.